GlassScriptPhysician profile
Phillip L Brick
NPI 1689787459
$9,994.20
in general payments reported to CMS, 2019-2025
51 companies · $1,350 in 2025
The $1,350 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,983 · 2020: $659 · 2021: $1,860 · 2022: $1,444 · 2023: $1,186 · 2024: $1,512 · 2025: $1,350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,047.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,047.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,856.74 | 2020-2025 | Ubrelvy, Vraylar, Linzess |
| Novo Nordisk INC | $1,383.62 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $740.09 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $673.04 | 2019-2024 | Spravato, Xarelto |
| Pfizer INC. | $625.76 | 2019-2025 | |
| Amgen INC. | $466.78 | 2019-2025 | Evenity, Prolia, Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $402.07 | 2019-2024 | Jardiance |
| Amarin Pharma, INC. | $389.14 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $373.50 | 2019-2025 | |
| Glaxosmithkline, LLC. | $359.27 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $318.54 | 2020-2025 | Verquvo, Belsomra, Steglatro |
| Astrazeneca Pharmaceuticals LP | $266.86 | 2019-2025 | Breztri, Farxiga, Evusheld |
| Sanofi-Aventis U.S. LLC | $233.07 | 2019-2024 | |
| Allergan, INC. | $231.75 | 2019-2020 | |
| Horizon Therapeutics Plc | $137.13 | 2019-2023 | Krystexxa |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Brick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.